TABLE 3.

Oncotherapeutic Agents Approved Since 2018 With No Mention of Hepatic Adverse Events on the Product Label

Drug (Ref)	Drug Class/Therapeutic Use
Tumorocentric drugs
Enfortumab vedotin-ejfv76	Nectin-4–directed antibody-drug conjugate/urothelial cancer
Apalutamide77	Androgen receptor inhibitor/prostate cancer
Selinexor78	Nuclear export inhibitor/RRMM
Immuno-oncology drugs
Daratumumab + hyaluronidase79	CD38-directed cytolytic antibody + endoglycosidase/MM
Isatuximab-irfc80	CD38-directed cytolytic antibody/RRMM
Mogamulizumab-kpkc81	CCR4-directed monoclonal antibody/relapsed or refractory mycosis fungoides or Sézary syndrome after ≥1 prior systemic therapy

MM indicates multiple myeloma; RR, relapsed or refractory.